Bosutinib + Bosutinib
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML)
Conditions
Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML)
Trial Timeline
Aug 1, 2011 → Oct 1, 2011
NCT ID
NCT01374139About Bosutinib + Bosutinib
Bosutinib + Bosutinib is a phase 1 stage product being developed by Pfizer for Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML). The current trial status is completed. This product is registered under clinical trial identifier NCT01374139. Target conditions include Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML).
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01374139 | Phase 1 | Completed |
| NCT00721474 | Phase 1 | Completed |
Competing Products
20 competing products in Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Imatinib Mesylate | Novartis | Phase 2 | 52 |
| Nilotinib | Novartis | Phase 3 | 77 |
| Nilotinib | Novartis | Phase 3 | 77 |
| STI571 400 mg + STI571 600 mg | Novartis | Phase 2 | 52 |
| Induction Phase + Re-Induction Phase + Post-Remission + Maintenance | Novartis | Phase 2 | 52 |
| nilotinib | Novartis | Phase 2 | 52 |
| Asciminib + Nilotinib | Novartis | Phase 3 | 77 |
| imatinib mesylate | Novartis | Phase 2 | 52 |
| Blinatumomab + Asciminib | Novartis | Phase 1/2 | 41 |
| Asciminib | Novartis | Phase 1 | 33 |
| Asciminib Pediatric formulation group + Asciminib Adult formulation group | Novartis | Phase 1/2 | 41 |
| Nilotinib + LDE225 | Novartis | Phase 1 | 33 |
| Nilotinib | Novartis | Approved | 85 |
| Imatinib + Nilotinib + Bosutinib + Dasatinib + Asciminib | Novartis | Phase 3 | 77 |
| Asciminib | Novartis | Approved | 85 |
| Blinatumomab | Amgen | Phase 2 | 51 |
| Treatment with blinatumomab given subcutaneously. | Amgen | Phase 2 | 51 |
| Blinatumomab + Blinatumomab + HyperCVAD | Amgen | Phase 3 | 76 |
| Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimen | Amgen | Phase 3 | 76 |
| Bosutinib | Pfizer | Phase 1/2 | 40 |